TD Cowen maintained a Hold rating on Merck Sharp & Dohme on July 4, 2025.
1 report, 0 independent
Updated Jul 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen maintained a Hold rating on Merck Sharp & Dohme on July 4, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Merck Sharp & Dohme
company in Madrid, Spain
Nothing else this week.
Related events
- TD Cowen maintained a Buy rating on Forgent on September 15, 2026.
- TD Cowen downgraded Capri's rating and lowered its price target.
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- TD Cowen increased its target price to $3.00, while Jefferies Financial Group was involved in a rating update for Plug Power, with MarketBeat aggregating the consensus data.
Coverage
Newest first; wire copies grouped- Unknown outlet